Anti-GDF8/ GDF-8/ MSTN functional antibody

Anti-GDF8/ GDF-8/ MSTN functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to GDF-8/MSTN products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T87749-Ab-1/ GM-Tg-hg-T87749-Ab-2Anti-Human GDF-8/MSTN monoclonal antibodyHuman
GM-Tg-rg-T87749-Ab-1/ GM-Tg-rg-T87749-Ab-2Anti-Rat GDF-8/MSTN monoclonal antibodyRat
GM-Tg-mg-T87749-Ab-1/ GM-Tg-mg-T87749-Ab-2Anti-Mouse GDF-8/MSTN monoclonal antibodyMouse
GM-Tg-cynog-T87749-Ab-1/ GM-Tg-cynog-T87749-Ab-2Anti-Cynomolgus/ Rhesus macaque GDF-8/MSTN monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T87749-Ab-1/ GM-Tg-felg-T87749-Ab-2Anti-Feline GDF-8/MSTN monoclonal antibodyFeline
GM-Tg-cang-T87749-Ab-1/ GM-Tg-cang-T87749-Ab-2Anti-Canine GDF-8/MSTN monoclonal antibodyCanine
GM-Tg-bovg-T87749-Ab-1/ GM-Tg-bovg-T87749-Ab-2Anti-Bovine GDF-8/MSTN monoclonal antibodyBovine
GM-Tg-equg-T87749-Ab-1/ GM-Tg-equg-T87749-Ab-2Anti-Equine GDF-8/MSTN monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T87749-Ab-1/ GM-Tg-hg-T87749-Ab-2; GM-Tg-rg-T87749-Ab-1/ GM-Tg-rg-T87749-Ab-2;
GM-Tg-mg-T87749-Ab-1/ GM-Tg-mg-T87749-Ab-2; GM-Tg-cynog-T87749-Ab-1/ GM-Tg-cynog-T87749-Ab-2;
GM-Tg-felg-T87749-Ab-1/ GM-Tg-felg-T87749-Ab-2; GM-Tg-cang-T87749-Ab-1/ GM-Tg-cang-T87749-Ab-2;
GM-Tg-bovg-T87749-Ab-1/ GM-Tg-bovg-T87749-Ab-2; GM-Tg-equg-T87749-Ab-1/ GM-Tg-equg-T87749-Ab-2
Products NameAnti-GDF-8/MSTN monoclonal antibody
Formatmab
Target NameGDF-8
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-GDF-8 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-INN-967Pre-Made Ramatercept Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting GDF8/MSLHP
    BiosimilarGMP-Bios-INN-999Pre-Made Stamulumab Biosimilar, Whole Mab, Anti-MSTN/GDF-8 Antibody: Anti-GDF8/MSLHP therapeutic antibody
    BiosimilarGMP-Bios-ab-596Pre-Made Trevogrumab biosimilar, Whole mAb, Anti-MSTN/GDF-8 Antibody: Anti-GDF8/MSLHP therapeutic antibody
    BiosimilarGMP-Bios-ab-151Pre-Made Domagrozumab biosimilar, Whole mAb, Anti-MSTN/GDF-8 Antibody: Anti-GDF8/MSLHP therapeutic antibody
    BiosimilarGMP-Bios-ab-295Pre-Made Landogrozumab biosimilar, Whole mAb, Anti-MSTN/GDF-8 Antibody: Anti-GDF8/MSLHP therapeutic antibody
    BiosimilarGMP-Bios-INN-822Pre-Made Efmitermant Alfa Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG2 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting GDF8/MSLHP
    BiosimilarGMP-Bios-INN-1004Pre-Made Taldefgrobep Alfa Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting GDF8/MSLHP
    Target AntigenGM-Tg-g-T87749-Ag-1Recombinant multi-species GDF8/ GDF-8/ MSTN protein
    ORF Viral VectorpGMLPm002174mouse Mstn Lentivirus plasmid
    ORF Viral VectorvGMLPm002174mouse Mstn Lentivirus particle


    Target information

    Target IDGM-T87749
    Target NameGDF-8
    Gene ID2660,17700,29152,710114,403433,101081322,281187,100033832
    Gene Symbol and SynonymsCmpt,GDF8,MSLHP,MSTN
    Uniprot AccessionO14793,O35312,A1C2U6,Q6UKZ8,O18836,Q9GM97
    Uniprot Entry NameGDF8_HUMAN,GDF8_MACMU,GDF8_RAT,GDF8_CANLF,GDF8_BOVIN,GDF8_HORSE
    Protein Sub-locationSecreted Protein/Potential Cytokines
    CategoryTherapeutics Target, INN Index
    DiseaseN/A
    Gene EnsemblENSG00000138379
    Target ClassificationN/A

    The target: GDF-8, gene name: MSTN, also named as GDF8, MSLHP. This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression. The encoded preproprotein is proteolytically processed to generate each subunit of the disulfide-linked homodimer. This protein negatively regulates skeletal muscle cell proliferation and differentiation. Mutations in this gene are associated with increased skeletal muscle mass in humans and other mammals. [provided by RefSeq, Jul 2016].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.